Amgen Inc. (AMGN) has called it quits on the deal with AstraZeneca plc (AZN) for co-development and commercialization of Brodalumab, due to events of suicidal ideation and behavior in its clinical program, which the company believes would likely necessitate restrictive labeling for the drug.